An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice

Annals of Surgical Oncology

Volumn 5, Issue 1, 1998, Pages 93-99

  McCarty, Todd M ^a   Yu, Zhiwei ^a   Liu, Xiping ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cytotoxic T lymphocytes (CTL); p53 knockout; Transgenic mice

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; MOLECULAR CLONING; NONHUMAN; PROTEIN ANALYSIS; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD8; CELL CULTURE TECHNIQUES; FEMALE; GENES, P53; HLA-A ANTIGENS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031815345     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303770     Document Type: Article

References (38)

1. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093-6.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
4. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
5. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
6. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989;86:8763-7.
7. Oldstone MB, Tishon A, Geckeler R, Lewicki H, Whitton JL. A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc Natl Acad Sci USA 1992;89:2752-5.
8. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
9. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA. Identification of tumor-regression antigens in melanoma. In: DeVita V, Hellman S, Rosenberg S, eds. Important Advances in Oncology 1996. Philadelphia: Lippincott-Raven, 1996:3-21.
10. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-9.
11. Houbiers JG. Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
12. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol Lett 1994;40:171-8.
13. Ropke M, Hald J, Guldberg P, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996;93:14704-7.
14. Theobald M, Biggs J, Dittmer D, Levine A, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-7.
15. Koller BH, Orr HT. Cloning and complete sequence of an HLA-A2 gene: analysis of two HLA-A alleles at the nucleotidc level. J Immunol 1985;134:2727-33.
16. King DS, Fields CG, Fields GB. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res 1990;36:255-66.
17. Tiercy JM, Djavad N, Rufer N, Speiser DE, Jeannet M, Roosnek E. Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. Hum Immunol 1994;41: 207-15.
18. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
19. Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 1981;3:277-99.
20. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
21. Storkus WJ, Zeh HJ 3d, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J lmmunother 1993;14:94-103.
22. Wentworth PA, Celis E, Crimi C, et al. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol Immunol 1995;32:603-12.
23. D'Amaro J, Houbiers JG, Drijfhout JW, et al. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum Immunol 1995;43:13-8.
24. Yu Z. Liu X, McCarty TM, Diamond DJ, Ellenhorn JDI. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res 1997;69:337-43.
25. Bjorkman PJ, Saper MA. Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen. HLA-A2. Nature 1987;329:506-12.
26. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329: 512-8.
27. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am 1995;1:90-100.
28. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
29. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
30. Schlichtholz B, Legros Y, Gillet D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52:6380-4.
31. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
32. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc Natl Acad Sci USA 1996;93:4781-6.
33. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild type p53 specific cytotoxic T lymphocytes. Presented at Keystone Symposia: Cellular Immunology and the Immunotherapy of Cancer III 1997; Keystone, CO, February 1-7, 1997,31. Abstract.
34. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 1990;60:929-39.
35. Romeo C, Kolanus W, Amiot M, Seed B. Activation of immune system effector function by T-cell or Fc receptor intracellular domains. Cold Spring Harb Symp Quant Biol 1992;57:117-25.
36. Kolanus W, Romeo C, Seed B. Lineage-independent activation of immune system effector function by myeloid Fc receptors. EMBO J 1992;11:4861-8.
37. Hwu X, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993;178:361-6.
38. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-4.